<DOC>
	<DOCNO>NCT00348023</DOCNO>
	<brief_summary>Evaluate IOP-lowering efficacy quality life patient use bimatoprost 0.03 % monotherapy versus dual therapy travoprost 0.004 % timolol 0.5 % treatment glaucoma ocular hypertension .</brief_summary>
	<brief_title>Bimatoprost Monotherapy vs. Dual Therapy With Travoprost Timolol Patients With Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>· Male female &gt; 18 year age Diagnosis primary openangle glaucoma ocular hypertension Untreated IOP &gt; 18 mm Hg eye baseline evaluation Ability provide inform consent likely complete study visit · Known contraindication bimatoprost , travoprost , timolol , component study medication Uncontrolled systemic disease Active ocular disease POAG ocular hypertension Required use ocular medication study medication study ( intermittent use OTC artificial tear product permit ) History intraocular surgery within last 3 month Patient must discontinue use medication include study past reason efficacy intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
</DOC>